bavisant (JNJ-31001074) / J&J, BenevolentAI - LARVOL DELTA

In silico screening and preclinical validation identify bavisant as a therapeutic candidate for multiple sclerosis. (PubMed, Sci Transl Med) - "Our in vivo studies demonstrated that bavisant promoted remyelination and neuroprotection when administered to LPC-treated, cuprizone-fed, or MOG-induced EAE mice, as well as in a human oligodendroglia chimeric mouse model of demyelination/remyelination. These findings provide proof-of-concept validation for bavisant as a candidate for neuroprotective clinical trials in MS."

Journal • Preclinical • CNS Disorders • Multiple Sclerosis • Solid Tumor

CASPAR: BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness (clinicaltrials.gov) - P2 | N=244 | Completed | Sponsor: BenevolentAI Bio | Phase classification: P2b ➔ P2

Phase classification • CNS Disorders • Excessive Daytime Sleepiness • Movement Disorders • Parkinson's Disease • Sleep Disorder

"Ben 2001 mezunuyum." (@FFTB9501)

Histamine receptors, agonists, and antagonists in health and disease. (PubMed, Handb Clin Neurol) - "Pitolisant, a H3 receptor antagonist, is used to treat narcolepsy and hypersomnia...H2 receptor antagonists have shown efficacy in treatment of schizophrenia, but they are not in widespread clinical use. H4 receptor ligands may in the future be tested for neuroimmunological disorders and potentially neurodegenerative disorders in which inflammation plays a role, but clinical tests have not yet been initiated."

Journal • Allergy • CNS Disorders • Immunology • Inflammation • Insomnia • Narcolepsy • Peptic Ulcer • Psychiatry • Schizophrenia • Sleep Disorder